CHAPTER DosEmi study protocol: A phase IV, multicenter, open-label, crossover study to evaluate noninferiority of pharmacokineticguided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A Anouk A.M.T. Donners Konrad van der Zwet Toine C.G. Egberts Karin Fijnvandraat Ron A.A. Mathot Ilmar Kruis Marjon H. Cnossen Roger E.G. Schutgens Rolf T. Urbanus Kathelijn Fischer Submitted
RkJQdWJsaXNoZXIy MTk4NDMw